机构：[1]Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China[2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China[3]Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China河北大学附属医院[4]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China[5]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
第一作者机构：[1]Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Yongsheng,Yuan Peng,Yang Hua,et al.Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC)[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Wang, Yongsheng,Yuan, Peng,Yang, Hua,Liu, Yanbing,Yue, Jian...&Yu, Jinming.(2023).Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Wang, Yongsheng,et al."Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC)".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学